1:28
Ibrutinib and venetoclax: a powerful combination in frontline and relapsed CLL
Nitin Jain
2:42
iFCG yields unprecedented MRD negativity in CLL
Nitin Jain
2:14
Novel approaches to first line CLL treatment
Nitin Jain
2:26
Is venetoclax a game changer in AML therapy?
Alexander Perl
3:16
Overcoming venetoclax resistance in AML with MCL1 inhibition
Marina Konopleva
3:05
Current research in elderly, untreated AML: venetoclax combinations
Marina Konopleva
2:57
Genetic biomarkers of response to venetoclax in AML
Marina Konopleva
3:20
Venetoclax combinations effective in elderly AML
Marina Konopleva
1:56
Promising approaches and clinical trials in MDS
David Steensma
1:57
Breakthroughs in the treatment of elderly patients with AML
Farhad Ravandi
4:14
Future therapies for AML: bispecifics and small molecule inhibitors
Farhad Ravandi
3:27
Venetoclax: an unmet need in R/R mantle cell lymphoma after BTK inhibitors
Toby Eyre
1:12
Using biomarkers and genomics to inform treatment strategy in ALL
Thomas Alexander
2:43
Venetoclax combination therapy in relapsed ALL
Thomas Alexander
1:54
Does TP53-mutated clonal size impact outcomes of CLL patients from the MURANO study?
Arnon Kater
1:22
Promising outlooks for venetoclax combinations for MM
Shaji Kumar
VJHemOnc is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

VJHO needs the contact information you provide to inform you about our latest hemonc news and videos, educational courses and industry supported content (some of which may be promotional in nature). You may unsubscribe from these communications at anytime. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy.

The content of VJHemOnc is intended for healthcare professionals